Concepedia

Fagr Eladly

FE

Statistics

Publications

6

Citations

124

H-Index

6

Active since

2019

Affiliations

Goethe University Frankfurt(Current)

Heidelberg University

University Hospital Frankfurt

Frankfurt Cancer Institute

German Cancer Research Center

Fagr Eladly is an author at Goethe University Frankfurt specializing in medicine, oncology, and adverse effects of chemotherapy.

Publications per year

2019–2022

6

Publications

6

Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A

Elke Burgermeister, Francesca Battaglin, Fagr Eladly et al. · EBioMedicine · 2019 · 64 citations · Full text

Medicine, Oncology, Pharmacology +17

Use of carbapenems and glycopeptides increases risk for Clostridioides difficile infections in acute myeloid leukemia patients undergoing intensive induction chemotherapy

Olivier Balló, Eva‐Maria Kreisel, Fagr Eladly et al. · Annals of Hematology · 2020 · 14 citations · Full text

Medicine, Infectious Diseases, Pharmacology +16

Acute kidney injury adversely affects the clinical course of acute myeloid leukemia patients undergoing induction chemotherapy

Olivier Balló, Fagr Eladly, Stefan Büttner et al. · Annals of Hematology · 2021 · 13 citations · Full text

Medicine, Nephrology, Oncology +14

Reducing the red blood cell transfusion threshold from 8·0 g/dl to 7·0 g/dl in acute myeloid leukaemia patients undergoing induction chemotherapy reduces transfusion rates without adversely affecting patient outcome

Olivier Balló, Philine Fleckenstein, Fagr Eladly et al. · Vox Sanguinis · 2020 · 12 citations · Full text

Medicine, Hematology, Oncology +17

Current and Future Options of Haemophilia A Treatments

Wolfgang Miesbach, Fagr Eladly · Expert Opinion on Biological Therapy · 2021 · 11 citations

Medicine, Hematology, Pharmacotherapy +17

1–5 of 6